MCL1 and acute myeloid leukemia: On the basis of these results, first-in-human studies with a clinical-grade MCL-1 inhibitor are now being tested in combination with venetoclax in de novo, secondary, therapy-related, or R/R AML (NCT03672695), and in combination with decitabine in patients with MDS (NCT03593915).